Crestor, Serevent Are Among Problem Drugs Cited By FDA Safety Reviewer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx
You may also be interested in...
AstraZeneca Determined To Validate Crestor Safety, Toprol XL Patent Protection
AstraZeneca is looking to epidemiological data to demonstrate Crestor's safety profile
AstraZeneca Determined To Validate Crestor Safety, Toprol XL Patent Protection
AstraZeneca is looking to epidemiological data to demonstrate Crestor's safety profile
Grassley Stumbles In Comments On Meridia’s Regulatory History
Finance Committee chair criticizes lack of action on the obesity agent, but Abbott revised the product’s risk management plan nearly a year ago.